Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thrombokinetic Studies of Ado-Trastuzumab Emtansine

NCT01816035 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01816035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01816035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thrombokinetic Studies of Ado-Trastuzumab Emtansine
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2014
Completion date
April 30, 2017
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2/neu positive, recurrent breast carcinoma, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer